Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACOU085 for Prevention of Cisplatin-Induced Hearing Loss in Testicular Cancer
2023-503696-15-00Phase 2Completed
- Sponsor
- Acousia Therapeutics GmbH
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bimokalner in sensorineural hearing loss (SNHL), sponsored by Acousia Therapeutics GmbH. Started Sep 2023; status: completed.
02
Drugs
bimokalner
03
Conditions
sensorineural hearing loss (SNHL)
Beyond the preview
Go deeper on 2023-503696-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503696-15-00.